Altor licenses T-cell receptors targeting HIV and HCV from MGH.

The article reports on the agreement entered into by Altor BioScience Corp. with Massachusetts General Hospital for exclusive, worldwide rights to develop and commercialize T-cell receptors (TCRs) specific for cells infected by human immunodeficiency virus and hepatitis C virus in the U.S. It is noted that Altor has already successfully improved and converted the licensed TCRs into targeted therapeutic reagents using its Soluble T-cell Antigen Receptor technology.